Associated Papers
Protein-folding chaperones predict structure-function relationships and cancer risk in BRCA1 mutation carriers.
Gracia B et al.
Cell Reports, 2024
38368609 (PubMed )
Supplement: NIHMS1970903-supplement-6.xlsx › Table_S5
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
Saygin C et al.
Blood Advances, 2023
36001442 (PubMed )
Supplement: BLOODA_ADV-2022-008172-mmc1.pdf
Somatic variants of potential clinical significance in the tumors of BRCA phenocopies.
Buckingham L et al.
Hereditary Cancer in Clinical Practice, 2019
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
Mitchell R et al.
Plos One, 2018
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
Press JZ et al.
Neoplasia (new York, N.y.), 2010
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
van der Hout AH et al.
Human Mutation, 2006
Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers.
Kroiss R et al.
Human Mutation, 2005
Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.
Judkins T et al.
Cancer Research, 2005
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.
Piek JM et al.
The Journal of Pathology, 2001
Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients.
Papelard H et al.
British Journal of Cancer, 2000
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Ligtenberg MJ et al.
British Journal of Cancer, 1999
Select a paper to view details